CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 68 enrolled
Drug / intervention
Zoledronatedrug
Likely dose
Zoledronate 4 mg IV over 15 minutes once every 12 weeks for 4 dosesAI-extracted
Key inclusion· 4
  • ✓Postmenopausal women
  • ✓Stage III or axillary node positive breast cancer
  • ✓Currently disease free of breast cancer and other invasive malignancies at time of registration
  • ✓No concurrent use of bisphosphonates
Key exclusion· 1
  • ✕Metastatic disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00213980
NCT00213980Phase 2Completed
CompareCT.gov

Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

University of Wisconsin, Madison·interventional·Posted Sep 21, 2005·Updated Nov 27, 2019

In Brief

A Phase 2 clinical trial evaluating Zoledronate for Breast Cancer. Completed, enrolled 68 participants across 1 site.

Detailed Summary

This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2005
Enrollment StartJan 1, 2000
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 20.8 years ago

Interventions

Zoledronatedrug

4 mg IV over 15 minutes administered once every 12 weeks times 4